古文字学
发表于 2025-3-23 11:10:46
http://reply.papertrans.cn/67/6659/665855/665855_11.png
arthroplasty
发表于 2025-3-23 14:31:09
http://reply.papertrans.cn/67/6659/665855/665855_12.png
NEEDY
发表于 2025-3-23 22:05:05
Dabrafenib and Trametinibta confirming significant improvement in overall survival and progression-free survival over vemurafenib therapy or dabrafenib alone. The next indication in melanoma for the combination of these drugs is adjuvant therapy, which was approved on the basis of long-term outcomes of study resulting in a
Sad570
发表于 2025-3-23 22:42:31
http://reply.papertrans.cn/67/6659/665855/665855_14.png
Gastric
发表于 2025-3-24 05:57:51
http://reply.papertrans.cn/67/6659/665855/665855_15.png
外形
发表于 2025-3-24 09:26:20
Vismodegib and differentiation. Hh pathway is inactive in most normal adult tissues, and this pathway reactivation is involved in the pathogenesis of several malignancies like basal cell carcinoma. Vismodegib has been approved for locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
debase
发表于 2025-3-24 12:34:50
http://reply.papertrans.cn/67/6659/665855/665855_17.png
COKE
发表于 2025-3-24 17:57:34
http://reply.papertrans.cn/67/6659/665855/665855_18.png
苦涩
发表于 2025-3-24 21:10:37
Nivolumab in Melanoma: An Overview of Medical Literature and Future Perspectivesand adjuvant treatment of melanoma. The first checkpoint inhibitor to be approved by FDA and EMA for treatment of melanoma was ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, based on proven benefit in terms of overall survival and recurrence-free survival in advanced and ear
Hippocampus
发表于 2025-3-25 00:41:36
http://reply.papertrans.cn/67/6659/665855/665855_20.png